Overview

OrganAI Health is developing DiagnOptics™ –a compact, non-ionizing, lab-free medical device, powered with A.I. Our patent-pending invention rapidly and precisely quantifies and qualifies chemical composition, molecular structures, and critical disease pathologies (kidney diseases, first) in these targets: whole blood (cuvette), label-stain-free tissues, whole organ (deceased donor ex vivo, in vivo, in situ), and pharmaceuticals (for composition, concentration, and degradation). Our diagnostic solution enjoys criticality and feasibility in two fundamentally distinct, yet parallel biospheres Earth and Space each with stark deviations in established truths and the scientific laws offered as support. However, amidst such biodiversity devoid constants controls on Earth known truths to inform critical solutions lesser understood Space Dynamically conceived through a combination of advancements straddling such domains as aerospace engineering, optics, electronics, metasurface nanophotonics, spectral biosensing, and physics-enabled computational analysis to deliver to mutually beneficial (LEO microgravity; ISS excursions; extended Mars & Moon missions; physiological and microbiological research; extreme condition, military/battlefield triage; remote/limited resource geographies, as well as common terrestrial in-hospital applications. done by selecting known relevant wavelengths generated for each pixel in a machine learning algorithm, filtered for the camera’s optical signal, and finally applying the filters to a real-color image output containing pixel by pixel chemical signatures. High-resolution, rich “Hypercubes” inform transplant teams about the organ’s viability based on the same datapoints traditionally acquired with needle biopsy plus OrganAI’s additional, proprietary sensor and electronic integrations now in development. DiagnOptics™ is the first of its kind in non-invasive phenotyping.